Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 12/20 | 0.55 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.55 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13814439 | 1.00 | SIRT2 (0.55) | SIRT2SIRT1SIRT3SIRT5MEN1 | |
| SCHEMBL31559077 | 0.93 | SIRT5 (0.57) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL22387792 | 0.92 | SIRT2 (0.54) | SIRT2SIRT1SIRT3SIRT5MEN1 | |
| SCHEMBL19783968 | 0.92 | SIRT2 (0.53) | SIRT2SIRT1SIRT3SIRT5MEN1 | |
| SCHEMBL25932816 | 0.91 | SIRT5 (0.62) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL30527290 | 0.91 | SIRT5 (0.62) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL31558965 | 0.91 | SIRT2 (0.50) | SIRT2SIRT1SIRT3SIRT5CA2 | |
| SCHEMBL20888703 | 0.89 | SIRT2 (0.51) | SIRT2SIRT1SIRT3SIRT5MEN1 | |
| SCHEMBL31558966 | 0.89 | SIRT5 (0.49) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL18099942 | 0.89 | SIRT2 (0.58) | SIRT2SIRT1SIRT3SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630742-B1 | CHEMILUMINESCENT PROBES FOR IMAGING/DETECTION OF PROTEASES | UNIV RAMOT (IL) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023150543-A1 | PHOSPHORAMIDATE-BASED PSMA-TARGETED SMALL-MOLECULE DRUG CONJUGATES | CANCER TARGETED TECHNOLOGY LLC (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20200277647-A1 | CHEMILUMINESCENT PROBES FOR IMAGING/DETECTION OF PROTEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277647-A1 | CHEMILUMINESCENT PROBES FOR IMAGING/DETECTION OF PROTEASES | ADAM12, ADAM17, PRCP | SIRT2 1810/4885SIRT1 1276/4885SIRT3 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.